{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:17:26Z","timestamp":1778505446757,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81901162"],"award-info":[{"award-number":["81901162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Natural Science Foundation","doi-asserted-by":"crossref","award":["23ZR1441200"],"award-info":[{"award-number":["23ZR1441200"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15926-2","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:35:30Z","timestamp":1774935330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative outcomes of retreatment vs follow-up in DTC patients with intermediate response following initial radioactive iodine therapy: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiaxin","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"15926_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato M, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10:264\u201372.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"15926_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","volume":"9","author":"A Miranda-Filho","year":"2021","unstructured":"Miranda-Filho A, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9:225\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"15926_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid Off J Am Thyroid Assoc. 2016;26:1\u2013133.","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"15926_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review. JAMA. 2024;331:425\u201335.","journal-title":"JAMA"},{"key":"15926_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841\u2013985.","journal-title":"Thyroid"},{"key":"15926_CR6","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3390\/cancers16173096","volume":"16","author":"SK Newman","year":"2024","unstructured":"Newman SK, Patrizio A, Boucai L. Decision variables for the use of radioactive iodine in patients with thyroid cancer at intermediate risk of recurrence. Cancers. 2024;16:3096.","journal-title":"Cancers"},{"key":"15926_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"Tuttle RM, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341\u20139.","journal-title":"Thyroid"},{"key":"15926_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1365-2265.2012.04342.x","volume":"77","author":"F Vaisman","year":"2012","unstructured":"Vaisman F, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf). 2012;77:132\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"15926_CR9","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.3390\/cancers15164196","volume":"15","author":"L Piscopo","year":"2023","unstructured":"Piscopo L, et al. Efficacy of empirical radioiodine therapy in patients with differentiated thyroid cancer and elevated serum thyroglobulin without evidence of structural disease: a propensity score analysis. Cancers. 2023;15:4196.","journal-title":"Cancers"},{"key":"15926_CR10","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet Lond Engl. 2016;388:2783\u201395.","journal-title":"Lancet Lond Engl"},{"key":"15926_CR11","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/cancers15041270","volume":"15","author":"D Albano","year":"2023","unstructured":"Albano D, et al. Temporal evolution and prognostic role of indeterminate response sub-groups in patients with differentiated thyroid cancer after initial therapy with radioiodine. Cancers. 2023;15:1270.","journal-title":"Cancers"},{"key":"15926_CR12","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/en.2019-00315","volume":"160","author":"T Trybek","year":"2019","unstructured":"Trybek T, et al. Impact of BRAF V600E and TERT promoter mutations on response to therapy in papillary thyroid cancer. Endocrinology. 2019;160:2328\u201338.","journal-title":"Endocrinology"},{"key":"15926_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1210\/jc.2017-01790","volume":"103","author":"D Hirsch","year":"2018","unstructured":"Hirsch D, et al. Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease. J Clin Endocrinol Metab. 2018;103:469\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"15926_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s12020-024-04027-4","volume":"87","author":"P Malandrino","year":"2025","unstructured":"Malandrino P, et al. Consider or not consider: the unsolved question on the use of radioactive iodine for differentiated thyroid cancer with low to intermediate risk of recurrence. Endocrine. 2025;87:658\u201366.","journal-title":"Endocrine"},{"key":"15926_CR15","first-page":"5873897","volume":"2018","author":"J Shim","year":"2018","unstructured":"Shim J, Rao J, Yu R. Spontaneous regression of metastatic papillary thyroid cancer in a lymph node. Case Rep Endocrinol. 2018;2018:5873897.","journal-title":"Case Rep Endocrinol"},{"key":"15926_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000511708","volume":"10","author":"N Mukhtar","year":"2021","unstructured":"Mukhtar N, Aljamei H, Aljomaiah A, Moria Y, Alzahrani AS. Natural course of the American Thyroid Association response to therapy statuses (dynamic risk stratification) in differentiated thyroid cancer. Eur Thyroid J. 2021;10:198\u2013207.","journal-title":"Eur Thyroid J"},{"key":"15926_CR17","doi-asserted-by":"publisher","first-page":"1217092","DOI":"10.3389\/fendo.2023.1217092","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, et al. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy. Front Endocrinol. 2023;14:1217092.","journal-title":"Front Endocrinol"},{"key":"15926_CR18","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.3390\/cancers13174338","volume":"13","author":"M Klain","year":"2021","unstructured":"Klain M, et al. Long-term prognostic value of the response to therapy assessed by laboratory and imaging findings in patients with differentiated thyroid cancer. Cancers. 2021;13:4338.","journal-title":"Cancers"},{"key":"15926_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1530\/EJE-20-1073","volume":"184","author":"C Sa\u00efe","year":"2021","unstructured":"Sa\u00efe C, et al. Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients. Eur J Endocrinol. 2021;184:667\u201376.","journal-title":"Eur J Endocrinol"},{"key":"15926_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/thy.2023.0709","volume":"34","author":"DW Chen","year":"2024","unstructured":"Chen DW, et al. Survival prognostication in patients with differentiated thyroid cancer and distant metastases: a SEER population-based study. Thyroid. 2024;34:837\u201345.","journal-title":"Thyroid"},{"key":"15926_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijsu.2017.12.029","volume":"50","author":"YK So","year":"2018","unstructured":"So YK, Kim MJ, Kim S, Son YI. Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location. Int J Surg. 2018;50:94\u2013103.","journal-title":"Int J Surg"},{"key":"15926_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1089\/thy.2015.0429","volume":"26","author":"S Siddiqui","year":"2016","unstructured":"Siddiqui S, et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid. 2016;26:807\u201315.","journal-title":"Thyroid"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15926-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15926-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15926-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:02:04Z","timestamp":1778504524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15926-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15926"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15926-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Approval No. XHEC-D-2025-154) and complied with the Declaration of Helsinki. The requirement for informed consent was waived by the committee due to the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"594"}}